Home LiteratureArticle Details
PMID: 19018454 Published · ppublish English Journal Article

Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis.

Journal of bone and mineral metabolism ·Vol. 27 ·No. 1 ·2009-00-00 ·Pages 76-82

Kaji H, Hisa I, Inoue Y, Naito J, Sugimoto T, Kasuga M

Abstract

Bisphosphonate is an effective drug to reduce fracture risk in osteoporotic patients; however, factors affecting the efficacy of bisphosphonate treatment are not fully known, especially in Japanese patients. In the present study, we examined the relationships between an increase in lumbar spine bone mineral density (BMD) by bisphosphonates and several pretreatment parameters, including biochemical, bone/mineral, and body composition indices, in 85 postmenopausal osteoporotic patients treated with alendronate or risedronate. BMD increase was measured by dual-energy X-ray absorptiometry at the lumbar spine before and 2 years after treatment. BMD increase at the lumbar spine was observed as independent of age, height, weight, body mass index, and fat mass, although lean body mass seemed slightly related. On the other hand, fasting plasma glucose (FPG) levels were significantly and positively related to BMD increase at the lumbar spine. In multiple regression analysis, FPG levels were not significantly related to BMD increase at the lumbar spine when lean body mass was considered. As for bone/mineral parameters, BMD increase at the lumbar spine was not significantly related to serum levels of calcium, parathyroid hormone (PTH), and alkaline phosphatase or urinary levels of deoxypiridinoline and calcium excretion. As for BMD parameters, Z-scores of BMD at any site and bone geometry parameters obtained by forearm peripheral quantitative computed tomography were not significantly related to BMD increase at the lumbar spine. BMD increases at the lumbar spine were similar between groups with or without vertebral fractures. In conclusion, BMD increase at the lumbar spine by bisphosphonate treatment was not related to any pretreatment parameters, including body size, body composition, and bone/mineral metabolism in postmenopausal Japanese women with primary osteoporosis, although FPG correlated partly to BMD through lean body mass.

MeSH Terms
Absorptiometry, Photon Aged Aged, 80 and over Bone Density Bone Density Conservation Agents/pharmacology,therapeutic use Diphosphonates/pharmacology,therapeutic use Female Humans Lumbar Vertebrae/anatomy & histology,drug effects Middle Aged Osteoporosis, Postmenopausal/drug therapy,pathology
Chemicals
Bone Density Conservation Agents Diphosphonates
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Kaji Hiroshi
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. [email protected]
Hisa Itoko
Inoue Yoshifumi
Naito Junko
Sugimoto Toshitsugu
Kasuga Masato
References (34)
34 references, click to expand
  1. Determinants of bone mineral density and spinal fracture risk in postmenopausal Japanese women.
    Osteoporos Int. 2001;12(7):548-54 PMID: 11527051
  2. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study.
    J Clin Endocrinol Metab. 2006 Sep;91(9):3404-10 PMID: 16804043
  3. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation.
    Endocrinology. 2003 Jan;144(1):346-52 PMID: 12488363
  4. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004).
    J Bone Miner Metab. 2005;23(2):105-9 PMID: 15750687
  5. Localization of regional forearm bone loss from high resolution computed tomographic images.
    Osteoporos Int. 1991 Feb;1(2):76-80 PMID: 1790396
  6. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study.
    Osteoporos Int. 2005 Dec;16(12):1713-20 PMID: 15940395
  7. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women.
    Diabetes Care. 2001 Jul;24(7):1192-7 PMID: 11423501
  8. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
    J Bone Miner Res. 2006 Feb;21(2):292-9 PMID: 16418785
  9. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.
    Endocr Rev. 2002 Aug;23(4):517-23 PMID: 12202466
  10. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study.
    J Bone Miner Res. 2004 May;19(5):752-8 PMID: 15068498
  11. Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells.
    J Bone Miner Res. 1995 Jul;10(7):1050-6 PMID: 7484280
  12. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    J Bone Miner Res. 2004 Feb;19(2):323-9 PMID: 14969403
  13. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.
    Osteoporos Int. 2005 May;16(5):475-82 PMID: 15875093
  14. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    N Engl J Med. 1995 Nov 30;333(22):1437-43 PMID: 7477143
  15. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly.
    J Clin Endocrinol Metab. 2001 Jul;86(7):3086-90 PMID: 11443171
  16. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk.
    J Clin Endocrinol Metab. 2006 Sep;91(9):3355-63 PMID: 16735485
  17. Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women.
    J Bone Miner Res. 2001 Aug;16(8):1408-15 PMID: 11499863
  18. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.
    J Clin Endocrinol Metab. 2002 Apr;87(4):1586-92 PMID: 11932287
  19. Osteoporosis in patients with diabetes mellitus.
    J Bone Miner Res. 2007 Sep;22(9):1317-28 PMID: 17501667
  20. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.
    J Bone Miner Res. 2007 Apr;22(4):503-8 PMID: 17243862
  21. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
    Endocr Rev. 2002 Aug;23(4):508-16 PMID: 12202465
  22. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
    J Bone Miner Res. 2005 Jun;20(6):971-6 PMID: 15883637
  23. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    J Bone Miner Res. 2005 Dec;20(12):2097-104 PMID: 16294263
  24. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects.
    J Clin Endocrinol Metab. 2003 Oct;88(10):4655-8 PMID: 14557436
  25. Bone mineral density in adults with the metabolic syndrome: analysis in a population-based U.S. sample.
    J Clin Endocrinol Metab. 2007 Nov;92(11):4161-4 PMID: 17785365
  26. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
    JAMA. 1998 Dec 23-30;280(24):2077-82 PMID: 9875874
  27. Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus.
    J Clin Endocrinol Metab. 1995 Apr;80(4):1194-202 PMID: 7714089
  28. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis.
    Osteoporos Int. 2007 Apr;18(4):427-44 PMID: 17068657
  29. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition.
    Am J Clin Nutr. 1990 Jun;51(6):1106-12 PMID: 2349926
  30. Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study.
    Osteoporos Int. 2007 Oct;18(10):1337-44 PMID: 17492393
  31. Body size and hip fracture risk in older women: a prospective study. Study of Osteoporotic Fractures Research Group.
    Am J Med. 1997 Oct;103(4):274-80 PMID: 9382119
  32. Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women.
    Calcif Tissue Int. 2006 Jan;78(1):18-24 PMID: 16397738
  33. Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
    Osteoporos Int. 2005 Dec;16(12):1591-6 PMID: 16362147
  34. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study.
    J Clin Endocrinol Metab. 2002 Oct;87(10):4482-9 PMID: 12364423
Article Info
Journal
Journal of bone and mineral metabolism
Abbr.
J Bone Miner Metab
ISSN
0914-8779
DOI
10.1007/s00774-008-0005-y
Email
[email protected]
Published
2009-00-00
Epub
2008-00-19
Pages
76-82
Language
English
Region
Japan
NLM ID
9436705
Subset
IM
External Links
PubMed source DOI: 10.1007/s00774-008-0005-y View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2